These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 33201636

  • 1. [New and old glucose lowering drugs; a state-of-the-art review].
    IJzerman RG, Vrijlandt PJWS.
    Ned Tijdschr Geneeskd; 2020 Oct 15; 164():. PubMed ID: 33201636
    [Abstract] [Full Text] [Related]

  • 2. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE, van den Donk M, Wiersma T.
    Ned Tijdschr Geneeskd; 2019 Jan 14; 163():. PubMed ID: 30676706
    [Abstract] [Full Text] [Related]

  • 3. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 4. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 5. Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.
    Brønden A, Christensen MB, Glintborg D, Snorgaard O, Kofoed-Enevoldsen A, Madsen GK, Toft K, Kristensen JK, Højlund K, Hansen TK, Søndergaard E, Hansen KB.
    Diabet Med; 2023 Aug 07; 40(8):e15157. PubMed ID: 37249579
    [Abstract] [Full Text] [Related]

  • 6. Advances in the management of diabetes: therapies for type 2 diabetes.
    Tsoutsouki J, Wunna W, Chowdhury A, Chowdhury TA.
    Postgrad Med J; 2020 Oct 07; 96(1140):610-618. PubMed ID: 32467106
    [Abstract] [Full Text] [Related]

  • 7. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L, Adler S.
    Postgrad Med; 2018 May 07; 130(4):381-393. PubMed ID: 29667921
    [Abstract] [Full Text] [Related]

  • 8. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME, Kosiborod M.
    Am J Cardiol; 2019 Dec 15; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [Abstract] [Full Text] [Related]

  • 9. Treatment trajectories for Danish individuals with type 2 diabetes in the era of emerging glucose-lowering therapies.
    Pottegård A, Andersen JH, Søndergaard J, Rasmussen L, Kildegaard H, Vilsbøll T, Thomsen RW.
    Diabetes Obes Metab; 2024 Nov 15; 26(11):4996-5004. PubMed ID: 39284788
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL, Davis TME.
    Clin Ther; 2017 May 15; 39(5):1012-1025. PubMed ID: 27863704
    [Abstract] [Full Text] [Related]

  • 11. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T, Iwasaki K, Maedera S, Ito K, Takeshima T, Noma H, Shojima N.
    Curr Med Res Opin; 2020 Mar 15; 36(3):403-409. PubMed ID: 31855074
    [Abstract] [Full Text] [Related]

  • 12. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F, La Sala L, Rydén L, Marx N, Ferrini M, Valensi P, Ceriello A.
    Eur J Prev Cardiol; 2019 Dec 15; 26(2_suppl):73-80. PubMed ID: 31766918
    [Abstract] [Full Text] [Related]

  • 13. Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020-Nationwide Data from a Register-Based Analysis.
    Jermendy G, Kiss Z, Rokszin G, Abonyi-Tóth Z, Lengyel C, Kempler P, Wittmann I.
    Medicina (Kaunas); 2022 Oct 01; 58(10):. PubMed ID: 36295543
    [Abstract] [Full Text] [Related]

  • 14. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A.
    Diabetes Metab Res Rev; 2012 Dec 01; 28 Suppl 2():21-5. PubMed ID: 23280862
    [Abstract] [Full Text] [Related]

  • 15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun 01; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 16. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK, Ye C, Campbell S, Retnakaran R.
    JACC Heart Fail; 2018 Oct 01; 6(10):823-830. PubMed ID: 30196071
    [Abstract] [Full Text] [Related]

  • 17. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
    Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS.
    Int J Mol Sci; 2020 Sep 18; 21(18):. PubMed ID: 32961860
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect.
    Gómez-Huelgas R, Sanz-Cánovas J, Cobos-Palacios L, López-Sampalo A, Pérez-Belmonte LM.
    Eur J Intern Med; 2022 Feb 18; 96():26-33. PubMed ID: 34799233
    [Abstract] [Full Text] [Related]

  • 19. Glucose-lowering medicines for type 2 diabetes.
    Davoren P.
    Aust Fam Physician; 2015 May 18; 44(5):176-9. PubMed ID: 26042396
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS.
    Postgrad Med; 2017 Nov 18; 129(8):811-821. PubMed ID: 28749197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.